Cite
HARVARD Citation
D'Adda, M. et al. (2019). The e13a2 BCR‐ABL transcript negatively affects sustained deep molecular response and the achievement of treatment‐free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer. 125 (10), pp. 1674-1682. [Online].